Feature

Could home care replace inpatient HSCT?


 

One patient’s experience

Beth Vanderkin said it was “a blessing” to receive care at home after undergoing HSCT at Duke.

Beth Vanderkin is a transplant patient

Beth Vanderkin

Ms. Vanderkin was diagnosed with diffuse large B-cell lymphoma in 2014. After two chemotherapy regimens failed to shrink the tumor in her chest, she underwent radiotherapy and responded well. When a PET scan revealed the tumor had gone completely, she proceeded to transplant.

She received a haploidentical HSCT using cells donated by her eldest daughter, Hannah Eichhorst. Ms. Vanderkin received the transplant in the hospital, and for 2 weeks after that, she made daily visits to the transplant clinic.

After those 2 weeks, Ms. Vanderkin continued her treatment at home. Like other patients eligible for home care, Ms. Vanderkin lived close to Duke, had a caregiver available, and had passed a home inspection. The Duke team shipped the needed medical supplies to her house and arranged twice-daily visits from nurses and daily video calls with a doctor.

Ms. Vanderkin said receiving care at home was “a game changer.” She derived comfort from recovering in her own environment, could spend more time with her family, and didn’t have to miss special events. While receiving care at home, Ms. Vanderkin attended the homecoming event where her son, Josiah, was part of the court. Wearing a face mask and carrying a portable pump in her purse, Ms. Vanderkin joined other mothers in escorting their children onto the football field.

“I got to escort my son out onto the field, and he was crowned king that night,” Ms. Vanderkin said. “I didn’t do a lot of things [while receiving care at home], but there were things I didn’t have to miss because I was at home and not in the hospital.”

Ms. Vanderkin said home care was also beneficial for her husband, who was her caregiver. Thomas Vanderkin was able to work from home while caring for his wife, and the daily nurses’ visits allowed him to run errands without having to leave Ms. Vanderkin alone.

Since her experience with home care, Ms. Vanderkin has spent many more days in the hospital and clinic. She experienced a relapse after the transplant and went on to receive more chemotherapy as well as ipilimumab. She responded to that treatment and has now been cancer-free for 3 years.

The ipilimumab did cause side effects, including intestinal problems that resulted in the need for parenteral nutrition. This side effect was made more bearable, Ms. Vanderkin said, because she was able to receive the parenteral nutrition at home. She and her husband were comfortable with additional home care because of their positive experience with posttransplant care.

“I think we’re conditioned to think that, to receive the best care, we have to be sitting in a hospital room or a clinic, but I think there’s a lot of things we can probably do at home,” Ms. Vanderkin said. “And we might fare a lot better as patients if we’re in an environment that we feel comfortable in.”

Recommended Reading

FDA grants UCB product orphan designation
B-Cell Lymphoma ICYMI
Transplant strategy not viable for aggressive B-NHL
B-Cell Lymphoma ICYMI
‘Excellent’ survival with HCT despite early treatment failure in FL
B-Cell Lymphoma ICYMI
Elderly NHL patients have higher NRM after HSCT
B-Cell Lymphoma ICYMI
Novel bispecific CAR shows promise in B-cell malignancies
B-Cell Lymphoma ICYMI
Haplo-HCT shows viability in DLBCL
B-Cell Lymphoma ICYMI
Dual-targeted CAR T shows ‘clinical signal’ in NHL
B-Cell Lymphoma ICYMI
ZUMA-1 update: Axi-cel responses persist at 2 years
B-Cell Lymphoma ICYMI
CLL, GVHD may raise risk for skin cancer after allo-HCT
B-Cell Lymphoma ICYMI
Monitoring, early intervention key to CAR T safety
B-Cell Lymphoma ICYMI